Skip to main content

Advertisement

SpringerLink
Log in

Effect of chemotherapy on quality of life in patients with non-small cell lung cancer

  • Review Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

This study was conducted to evaluate the extent to which quality of life (QoL) assessment has been incorporated into clinical trials of patients with advanced non-small cell lung cancer (NSCLC) receiving palliative chemotherapy.

Patients and methods

Phase III trials for patients with NSCLC treated with palliative chemotherapy were identified by a literature search of PubMed. All abstracts and relevant articles from August 1986 to October 2011 were reviewed. The primary focus was on (a) whether these articles had incorporated QoL as an endpoint, (c) what instruments were used to measure QoL and (c) impact of chemotherapy on QoL.

Results

There were 3,780 items indexed under ‘quality of life and lung cancer’. One hundred three studies were identified which measured QoL using validated QoL instruments. Fifty-five of these trials assessed the effects of palliative chemotherapy on QoL in patients with advanced NSCLC. The European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire was the most widely used questionnaire; other commonly used measurement scales used were the Functional Assessment of Cancer Therapy-Lung and the Lung Cancer Symptom Scale. The majority of studies showed that chemotherapy had a positive impact on QoL and disease-specific symptoms.

Conclusion

It is now widely accepted that QoL should be considered as a primary endpoint of treatment in patients with advanced lung cancer both in clinical practice and clinical trials to further define meaningful response. As the traditional outcome measures of survival and tumour response are poor in this population, QoL assessment may offer a more comprehensive approach to evaluating the relative risks and benefits associated with treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aaronson NK (1992) Assessing the quality of life of patients in cancer clinical trials. Common problems and common sense solutions. Eur J Cancer 28A:1304–1307

    PubMed  CAS  Google Scholar 

  2. Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ (1997) Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 15:744–749

    PubMed  CAS  Google Scholar 

  3. Akerly W, Glantz M, Choy H et al (1998) Phase II trial of weekly paclitaxel in advanced non-small cell lung cancer. J Clin Oncol 16:153–158

    Google Scholar 

  4. Anderson H, Hopwood P, Stephens RJ et al (2000) Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer—a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Br J Cancer 83:447–453

    PubMed Central  PubMed  CAS  Google Scholar 

  5. Baka S, Ashcroft L, Anderson M et al (2005) Randomized phase III study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status <70) and advanced non-small-cell lung cancer. J Clin Oncol 23:2136–2144

    PubMed  CAS  Google Scholar 

  6. Belani CP, Pereira JR, von Pawel J et al (2006) Effect of chemotherapy for advanced non-small cell lung cancer on patients’ quality of life. A randomized controlled trial. Lung Cancer 53:231–239

    PubMed  Google Scholar 

  7. Bergman B, Aaronson NK, Ahmedazi S et al (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30A:635–642

    PubMed  CAS  Google Scholar 

  8. Bergner M, Bobbitt RA, Carter WB et al (1981) The Sickness Impact Profile: development and final revision of a health status measure. Med Care 19:787–805

    PubMed  CAS  Google Scholar 

  9. Bonomi P, KyungMann K, Fairclough D et al (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623–672

    PubMed  CAS  Google Scholar 

  10. Borgstrom P, Gold DP, Hillian KJ et al (1999) Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEG neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19:4203–4214

    PubMed  CAS  Google Scholar 

  11. Bowling A (1991) A Review of Quality of Life Measurement Scales. Meas Health, Open University Press, Milton Keynes

  12. Bowling A (1995) A Review of Disease-Specific Quality of Life Measurement Scales. Meas Health, Open University Press, Milton Keynes

  13. Breathnach OS, Freidlin B, Conley B et al (2001) Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19:1734–1742

    PubMed  CAS  Google Scholar 

  14. Brown J, Thorpe H, Napp V et al (2005) Assessment of quality of life in the supportive care setting of The Big Lung Trial in non-small-cell lung cancer. J Clin Oncol 23:7417–7427

    PubMed  CAS  Google Scholar 

  15. Buccheri GF, Ferrigno D, Curcia A et al (1989) Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Cancer 63:428–432

    PubMed  CAS  Google Scholar 

  16. Bunn PA Jr, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review. Clin Cancer Res 5:1087–1100

    Google Scholar 

  17. Calman KC (1984) Quality of life in cancer patients: an hypothesis. J Med Ethics 10:124–127

    PubMed Central  PubMed  CAS  Google Scholar 

  18. Cardenal F, Lopez-Cabrerizo MP, Anton A et al (1999) Randomized phase III study of gemcitabine–cisplatin versus etoposide–cisplatin in the treatment of locally advanced or metastatic non small cell lung cancer. J Clin Oncol 17:12–18

    PubMed  CAS  Google Scholar 

  19. Carney DN, Hansen HH (2000) Non-small-cell lung cancer—stalemate or progress. N Engl J Med 343:1261–1262

    PubMed  CAS  Google Scholar 

  20. Cella DF, Bonomi AE, Lloyd SR et al (1995) Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12:199–220

    PubMed  CAS  Google Scholar 

  21. Cella D, Herbst RS, Lynch TJ et al (2005) Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 23:2946–2954

    PubMed  CAS  Google Scholar 

  22. Crino L, Scagliotti GV, Ricci S et al (1999) Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non small cell lung cancer: a randomised phase III study of the Italian Lung Cancer Project. J Clin Oncol 17:3522–3530

    PubMed  CAS  Google Scholar 

  23. Cullen MH, Billingham LJ, Woodroffe CM et al (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17(10):3188–3194

    PubMed  CAS  Google Scholar 

  24. Dancey J, Shepherd FA, Gralla RJ et al (2004) Quality of life assessment of second line docetaxel versus best supportive care in patients with non small cell lung cancer previously treated with platinum based chemotherapy: results of a prospective, randomised phase III trial. Lung Cancer 43:183–194

    PubMed  Google Scholar 

  25. de Haes JC, van Knippenburg FC, Neijit JP (1990) Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 62:1034–1038

    PubMed Central  PubMed  Google Scholar 

  26. Emmanuel LL, Barry MJ, Stoeckle JD et al (1991) Advance directives for medical care: a case for greater use. N Engl J Med 324:889–895

    Google Scholar 

  27. Fairclough DL (1997) Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med 16:1197–1209

    PubMed  CAS  Google Scholar 

  28. Fayers PM, Jones DR (1983) Measuring and analysing quality of life in cancer clinical trials: a review. Stat Med 2:429–446

    PubMed  CAS  Google Scholar 

  29. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676

    PubMed  CAS  Google Scholar 

  30. Fidias PM, Dakhil SR, Lyss AP et al (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 27:591–598

    PubMed  CAS  Google Scholar 

  31. Frasci G, Lorusso V, Panza N et al (2000) Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non small cell lung cancer. J Clin Oncol 18:2529–2536

    PubMed  CAS  Google Scholar 

  32. Fujino S, Enokibori T, Tezuka N et al (1996) A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small-cell lung cancer. Eur J Cancer 32A:2070–2074

    PubMed  CAS  Google Scholar 

  33. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 21:2237–2246

    PubMed  CAS  Google Scholar 

  34. Gatzemeier U, von Pawel J, Gottfried M et al (2000) Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 18:3390–3399

    PubMed  CAS  Google Scholar 

  35. Gebbia V, Lorusso V, Galetta D et al (2010) First line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale. Lung Cancer 69:218–224

    PubMed  Google Scholar 

  36. Georgoulias V, Papadakis E, Alexopoulos A et al (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: a randomized multicentre trial. Lancet 357:1478–1484

    PubMed  CAS  Google Scholar 

  37. Georgoulias V, Ardavanis A, Tsiafaki X et al (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23:2937–2945

    PubMed  CAS  Google Scholar 

  38. Giaccone G, Splinter TA, Debruyne C et al (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16:2133–2141

    PubMed  CAS  Google Scholar 

  39. Gill TM, Feinstein AR (1994) A critical appraisal of the quality of quality of life measurements. JAMA 272:619–626

    PubMed  CAS  Google Scholar 

  40. Greenlee RT, Hill-Harmon MB, Murray T, Thun T (2001) Cancer statistics, 2001. CA Cancer J Clin 51:15–36

    PubMed  CAS  Google Scholar 

  41. Gridelli C, Gallo C, Shepherd FA et al (2003) Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer. J Clin Oncol 21:3025–3034

    PubMed  CAS  Google Scholar 

  42. Gridelli C, Gallo C, Di Maio M et al (2004) A randomised clinical trial of two docetaxel regimens (weekly versus 3 week) in the second-line treatment of non-small-cell lung cancer: the DISTAL 01 study. Br J Cancer 91:1996–2004

    PubMed Central  PubMed  CAS  Google Scholar 

  43. Gridelli C, Kaukel E, Gregorc V et al (2007) Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol 2:221–229

    PubMed  Google Scholar 

  44. Grilli R, Oxman AD, Julian JA (1993) Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 11(10):1866–1872

    PubMed  CAS  Google Scholar 

  45. Gronberg BH, Bremnes RM, Flotten O et al (2009) Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27:3217–3224

    PubMed  Google Scholar 

  46. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597

    PubMed  CAS  Google Scholar 

  47. Helsing M, Bergman B, Thaning L et al (1998) Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer 34(7):1036–1044

    PubMed  CAS  Google Scholar 

  48. Herndon JE, Fleishman S, Kosty MP et al (1997) A longitudinal study of quality of life in advanced non-small-cell lung cancer: Cancer and Leukaemia Group B (CALGB) 8931. Control Clin Trials 18:286–300

    PubMed  CAS  Google Scholar 

  49. Hollen PJ, Gralla RJ (1996) Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol 23(suppl 5):31–40

    PubMed  CAS  Google Scholar 

  50. Hollen PJ, Gralla RJ, Kriss MG et al (1993) Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 29A(suppl 1):S51–58

    PubMed  Google Scholar 

  51. Joyce CRB (1994) Health status and quality of life: which matters to the patient? J Cardiovasc Pharmacol 23(suppl 3):26–33

    Google Scholar 

  52. Kelly K, Crowley J, Bunn PA Jr et al (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer. A Southwest Oncology Group trial. J Clin Oncol 19:3210–3218

    PubMed  CAS  Google Scholar 

  53. Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844

    PubMed  CAS  Google Scholar 

  54. Kosmidis P, Mylonakis N, Nicolaides C et al (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol 20:3578–3585

    PubMed  CAS  Google Scholar 

  55. Kubota K, Watanabe K, Kunitoh H et al (2004) Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non small cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22:254–261

    PubMed  CAS  Google Scholar 

  56. Laack E, Dickgreber N, Muller T et al (2004) Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 22:2348–2356

    PubMed  CAS  Google Scholar 

  57. Langer CJ, Leighton JC, Comis RL et al (1995) Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response and survival analysis. J Clin Oncol 13:1860–1870

    PubMed  CAS  Google Scholar 

  58. Langer CJ, Manolo J, Bernardo P et al (2002) Cisplatin based therapy for elderly patients with advanced NSCLC: implications of Eastern Co-operative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173–181

    PubMed  Google Scholar 

  59. Le Chevalier T, Pujol JL, Douillard JY et al (1994) A three arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis. Semin Oncol 21:28–33

    PubMed  Google Scholar 

  60. Leplege A, Hunt S (1997) The problem of quality of life in medicine. JAMA 278:47–50

    PubMed  CAS  Google Scholar 

  61. Lillenbaum RC, Chen CS, Chidiac T et al (2005) Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 16:97–101

    Google Scholar 

  62. Ma CX, Nair S, Thomas S et al (2005) Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front line therapy for advanced non-small-cell lung cancer. J Clin Oncol 25:5929–5937

    Google Scholar 

  63. Manegold G, Bergman B, Chemaissani A et al (1997) Single agent gemcitabine versus cisplatin-etoposide: early results of a randomized phase II study in locally advanced or metastatic non-small cell lung cancer. Ann Oncol 8:525–529

    PubMed  CAS  Google Scholar 

  64. Marino P, Pampallona S, Preatoni A et al (1994) Chemotherapy vs supportive care in advanced non-small-cell lung cancer: results of a meta-analysis of the literature. Chest 106(3):861–865

    PubMed  CAS  Google Scholar 

  65. Maruyama R, Nishiwaki Y, Tamura T et al (2008) Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 26:4244–4252

    PubMed  CAS  Google Scholar 

  66. Moinpour CM, Lyons B, Grevstad PK et al (2002) Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomised trial. Qual Life Res 11:115–126

    PubMed  Google Scholar 

  67. Mok T, Wu Y, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–57

    PubMed  CAS  Google Scholar 

  68. Montazeri A, Gillis CR, McEwen J (1998) Quality of life in patients with lung cancer: a review of literature from 1970–1995. Chest 113:467–81

    PubMed  CAS  Google Scholar 

  69. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311(7010):899–909

    Google Scholar 

  70. O’Boyle CA (1994) The schedule for the evaluation of individual quality of life. Int J Ment Health 23:3–23

    Google Scholar 

  71. O’Boyle CA, Waldron D (1997) Quality of life issues in palliative medicine. J Neurol 224(suppl 4):18–25

    Google Scholar 

  72. Olschewski M, Schulgen G, Schumacher M et al (1994) Quality of life assessment in clinical cancer research. Br J Cancer 70:1–5

    PubMed Central  PubMed  CAS  Google Scholar 

  73. Osoba D (1994) Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 12:608–616

    PubMed  CAS  Google Scholar 

  74. Osoba D (1996) Quality of life assessment in palliative medicine. Prog Palliat Care 4:167–168, editorial

    Google Scholar 

  75. Paccagnella A, Favaretto A, Oniga F et al (2004) Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 43:83–91

    PubMed  Google Scholar 

  76. Parkin DM, Pisani P, Ferlay J (1993) Estimation of the worldwide incidence of 18 major cancers in 1985. Int J Cancer 54:594–606

    PubMed  CAS  Google Scholar 

  77. Patrick DL, Erickson P (1993) Assessing health-related quality of life for clinical decision-making. In: Walker SR, Rosser RM (eds) Quality of life assessment: key issues for the 1990s. Kluwer Academic, London, pp 11–64

    Google Scholar 

  78. Patrick DL, Erickson P (1993) Health status and health policy: allocating resources to health care. Oxford University Press, New York, pp 3–26

    Google Scholar 

  79. Pavelic K, Banjac Z, Pavelic J et al (1993) Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 13:1133–1137

    PubMed  CAS  Google Scholar 

  80. Perng RP, Chen YM, Ming-Liu J et al (1997) Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 15:2097–2102

    PubMed  CAS  Google Scholar 

  81. Presant CA (1984) Quality of life in cancer patients: who measures what? Am J Clin Oncol 7:571–573

    PubMed  CAS  Google Scholar 

  82. Ranson M, Davidson N, Nicholson M et al (2000) Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92:1074–1080

    PubMed  CAS  Google Scholar 

  83. Richards T (1998) Partnership with patients. BMJ 316:85–86, editorial

    PubMed Central  PubMed  CAS  Google Scholar 

  84. Rosell R, Gatzmeier U, Betticher DC et al (2002) Phase III randomized trial comparing paclitaxel / carboplatin with paclitaxel / cisplatin in patients with advanced non small cell lung cancer: a co-operative multinational trial. Ann Oncol 13:1539–1549

    PubMed  CAS  Google Scholar 

  85. Roszkowski K, Pluzanska A, Krzakowski M et al (2000) Multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27:145–157

    PubMed  CAS  Google Scholar 

  86. Rudd RM, Gower NH, Spiro SG et al (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23:142–153

    PubMed  CAS  Google Scholar 

  87. Sandler A, Ettinger DS (1999) Gemcitabine; Single agent and combination therapy in non-small cell lung cancer. Oncologist 4:241–251

    PubMed  CAS  Google Scholar 

  88. Sandler AB, Ansari R, McClean J et al (1995) Gemcitabine plus cisplatin in non-small cell lung cancer: a phase II study. Eur J Cancer 31 A(suppl 5):S225

    Google Scholar 

  89. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550

    PubMed  CAS  Google Scholar 

  90. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

    PubMed  CAS  Google Scholar 

  91. Schipper H, Clinch J, McMurray A et al (1984) Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 2:472–483

    PubMed  CAS  Google Scholar 

  92. Schuette W, Nagel S, Blakenburg T et al (2005) Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23:8389–8395

    PubMed  CAS  Google Scholar 

  93. Sederholm C, Hillerdal G, Lamberg K et al (2005) Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 23:8380–8388

    PubMed  Google Scholar 

  94. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 19:2095–2103

    Google Scholar 

  95. Shepherd FA, Dancey J, Arnold A et al (2001) Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92:595–600

    PubMed  CAS  Google Scholar 

  96. Shepherd FA, Rodrigues PJ, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

    PubMed  CAS  Google Scholar 

  97. Silvestri G, Pritchard R, Welch G (1998) Preferences for chemotherapy in patients with advanced NSCLC: descriptive study based on scripted interviews. BMJ 317:771–775

    PubMed Central  PubMed  CAS  Google Scholar 

  98. Slevin ML, Plant H, Lynch D et al (1988) Who should measure quality of life, the doctor or the patient ? Br J Cancer 57:109–112

    PubMed Central  PubMed  CAS  Google Scholar 

  99. Smit EF, van Meerbeeck PAM, Lianes P et al (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel and gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Group—EORTC 08975. J Clin Oncol 21:3909–3917

    PubMed  CAS  Google Scholar 

  100. Smith IE, O’Brien MER, Talbot DC et al (2001) Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine and cisplatin. J Clin Oncol 19:1336–1343

    PubMed  CAS  Google Scholar 

  101. Socinski MA, Schell MJ, Peterman A et al (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20:1335–1343

    PubMed  CAS  Google Scholar 

  102. Souquet PJ, Chauvin F, Boissel JP et al (1993) Polychemotherapy in advanced non small cell lung cancer: a meta analysis. Lancet 342(8862):19–22

    PubMed  CAS  Google Scholar 

  103. Spilker B (ed) (1996) Quality of life and pharmacoeconomics in clinical trials (ed 2). Raven, New York, pp 1–10

    Google Scholar 

  104. Spiro SG, Rudd RM, Souhami RL et al (2004) Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 59:828–836

    PubMed Central  PubMed  CAS  Google Scholar 

  105. Spitzer WO, Dobson AJ, Hall J et al (1981) Measuring quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 34:585–597

    PubMed  CAS  Google Scholar 

  106. Temel J, Greer J, Muzikansky A et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742

    PubMed  CAS  Google Scholar 

  107. Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527–1537

    PubMed  CAS  Google Scholar 

  108. The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66–72

    Google Scholar 

  109. Thongprasert S, Sanguanmitra P, Juthapan W et al (1999) Relationship between quality of life and clinical outcomes in advanced non-small-cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 24(1):17–24

    PubMed  CAS  Google Scholar 

  110. Vansteenkiste J, Vandebroek J, Nackaerts K et al (2001) Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomized phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 12:1221–1230

    PubMed  CAS  Google Scholar 

  111. Varricchio CG, McCabe MS, Trimble E et al (1996) Quality of life in cancer clinical trials. J Natl Cancer Inst Monogr 20:vii–viii

    PubMed  Google Scholar 

  112. Volm M, Rittgen W, Drings P (1998) Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 77:663–669

    PubMed Central  PubMed  CAS  Google Scholar 

  113. von Plessen C, Bergman B, Andresen O et al (2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality of life benefits in advanced non-small-cell lung cancer. Br J Cancer 95:966–973

    Google Scholar 

  114. Waldron D, O’Boyle CA (1998) Individual quality of life in palliative care. In: Joyce CRB, O’Boyle CA, McGee H (eds) Individual quality of life approaches to conceptualisation and assessment in health. Harwood Academic, Reading, pp 197–211

    Google Scholar 

  115. Waldron DW, O’Boyle CA, Kearney ML et al (1999) Quality-of-life measurement in advanced cancer: assessing the individual. J Clin Oncol 17:3603–3611

    PubMed  CAS  Google Scholar 

  116. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors have no conflict of interest to declare in relation to sponsorship or authorship of this research. They have control of the content of this review and the journal can review the data if requested.

Author information

Authors and Affiliations

  1. Department of Palliative Medicine, Galway University Hospital, Newcastle Road, Galway, Ireland

    Eileen Mannion & Dympna Waldron

  2. Department of Respiratory Medicine, Galway University Hospital, Newcastle Road, Galway, Ireland

    J. J. Gilmartin

  3. Department of Medical Oncology, Galway University Hospital, Newcastle Road, Galway, Ireland

    Paul Donnellan & Maccon Keane

Authors
  1. Eileen Mannion
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. J. Gilmartin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Donnellan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maccon Keane
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dympna Waldron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eileen Mannion.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mannion, E., Gilmartin, J.J., Donnellan, P. et al. Effect of chemotherapy on quality of life in patients with non-small cell lung cancer. Support Care Cancer 22, 1417–1428 (2014). https://doi.org/10.1007/s00520-014-2148-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-014-2148-9

Keywords

Search

Navigation